Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Healios KK ( (JP:4593) ) has provided an update.
Healios K.K. has entered into an agreement with AND medical group to supply culture supernatant for new treatments and cosmetics. This agreement follows a joint research initiative and includes significant financial transactions, positioning Healios to expand its influence in regenerative medicine and enhance its market offerings.
More about Healios KK
Healios K.K. is a leading biotechnology company in Japan focused on regenerative medicine using stem cells. The company develops therapies for diseases lacking effective treatments, with proprietary platforms utilizing somatic and iPS cells. Healios is advancing products like MultiStem for ischemic stroke, ARDS, and trauma, and is working on next-generation treatments for solid tumors and other severe unmet medical needs.
YTD Price Performance: 12.99%
Average Trading Volume: 816,544
Technical Sentiment Consensus Rating: Hold
Current Market Cap: Yen18.12B
See more data about 4593 stock on TipRanks’ Stock Analysis page.